Completed PHASE1 INTERVENTIONAL 6-arm NCT03493191

A Single Dose Study of SHR0410 in Healthy Male Participants

A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous SHR0410 in Healthy Male Participants

Sponsor: Atridia Pty Ltd.

Conditions Acute Pain

Interventions 0.5μg/kg SHR0410 10μg/kg SHR0410 1μg/kg SHR0410 20μg/kg SHR0410 2μg/kg SHR0410 5μg/kg SHR0410

Updated 6 times since 2018 Last updated: Feb 25, 2019 Started: Apr 15, 2018 Primary completion: Jun 29, 2018 Completion: Jul 14, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Pain and is currently completed. Atridia Pty Ltd. leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

May 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atridia Pty Ltd.
Linear Clinical Research

Data source: Atridia Pty Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nedlands, Australia